A UCF cancer researcher is discovering ways that the body's own natural killer (NK) cells can be energized to fight deadly pediatric cancers and improve immunotherapy by unleashing the power of our immune system.
Jan 30, 2024
0
0
For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Jan 27, 2024
0
0
Although the incidence of cervical cancer has declined with increased screening and higher uptake of human papillomavirus (HPV) vaccination, cervical cancer remains the second highest cause of cancer mortality among women ...
Jan 25, 2024
0
0
Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos Vargas, a Mayo Clinic radiation ...
Jan 25, 2024
0
1
The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine. Researchers from the Perelman School of Medicine ...
Jan 25, 2024
0
8
Imaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather than the standard of around three months—identified metabolic changes that corresponded with treatment ...
Jan 24, 2024
0
0
Because low-risk prostate cancer is unlikely to spread or impact survival, experts and guidelines recommend active surveillance, which involves regular monitoring and thus avoids or delays treatment like surgery or radiation ...
Jan 22, 2024
0
0
Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly-used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.
Jan 22, 2024
0
15
Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived ...
Jan 18, 2024
0
12
A new research paper titled "Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response" has been published in Aging.
Jan 17, 2024
0
0
